Insulin Analogues

Insulin analogues are modified forms of human insulin developed utilizing recombinant DNA technology to overcome the pharmacokinetic limitations of traditional human regular and neutral protamine Hagedorn (NPH) insulins.
The primary therapeutic objective of utilizing insulin analogues is to safely and closely simulate the normal physiological pattern of pancreatic insulin secretion, which consists of a continuous, peakless basal output interspersed with rapid, intermittent meal-stimulated spikes.
Analogues are broadly categorized into rapid-acting, long-acting (basal), and ultra-long-acting formulations based on their engineered pharmacokinetic and pharmacodynamic profiles.

Rapid-Acting Insulin Analogues

The currently available rapid-acting analogues include insulin lispro, insulin aspart, and insulin glulisine.
These analogues are engineered via specific amino acid substitutions in the C-terminal region of the insulin B chain.
Native human regular insulin naturally self-aggregates into stable hexamers following subcutaneous injection, which delays its dissociation into absorbable monomers and prolongs its onset of action to 30 to 60 minutes.
The targeted amino acid modifications in rapid-acting analogues significantly reduce the affinity of the insulin molecules to self-aggregate into hexamers.
Because they remain primarily as monomers or rapidly dissociate, they are absorbed almost immediately from the subcutaneous tissue into the systemic circulation.
A newer, ultra-rapid-acting formulation known as fast-acting insulin aspart (Fiasp) has recently been approved, offering an even more accelerated onset of action.

Standard rapid-acting analogues exhibit an onset of action within 5 to 15 minutes (0.15–0.35 hours), reach peak effect at 1 to 3 hours, and possess a short overall duration of action of 3 to 5 hours.
Fast-acting insulin aspart (Fiasp) has an onset of action of 0.1 to 0.2 hours.
Clinically, this pharmacokinetic profile is highly advantageous because it tempers early postprandial hyperglycemic excursions more effectively than regular insulin while simultaneously reducing the risk of late postprandial hypoglycemia due to its short tail.
Because of their rapid onset, these analogues are ideally administered 10 to 15 minutes before a meal.
However, their rapid absorption allows them to be administered immediately before or even after meals, making them particularly ideal for infants and toddlers with unpredictable eating patterns or picky eating behaviors.
Rapid-acting analogues are the standard bolus insulin used in multiple daily injection (MDI) basal-bolus regimens and are the exclusive type of insulin utilized in continuous subcutaneous insulin infusion (CSII) pump therapy.

Long-acting analogues, namely insulin glargine and insulin detemir, were developed to provide a sustained, peakless background insulin level to suppress hepatic gluconeogenesis throughout the day and night.
Insulin Glargine: This analogue is created by the C-terminal elongation of the beta chain with two arginine residues, combined with the substitution of asparagine for glycine at position A21.
These specific chemical modifications render insulin glargine highly soluble in its acidic packaging solution but relatively insoluble at the neutral, physiological pH of the human subcutaneous tissue.
Consequently, upon injection, insulin glargine forms stable microprecipitates in the subcutaneous depot, which drastically delays its absorption and provides a prolonged duration of action.
Insulin Detemir: This analogue is modified by the covalent addition of a fatty acid side chain to the insulin molecule.
This fatty acid side chain promotes reversible binding with albumin both in the interstitial fluid at the injection site and within the systemic circulation, which delays its clearance and prolongs its metabolic effect.

Insulin glargine typically has an onset of action of 2 to 4 hours, is nearly peakless (or has a broad, blunted peak at 8 to 12 hours), and provides basal coverage for 22 to 24 hours.
Insulin detemir has an onset of 1 to 2 hours, a peak effect at 4 to 7 hours, and a duration of 20 to 24 hours.
Because there is considerable inter-individual variability in duration, insulin detemir is more frequently likely to require twice-daily dosing in pediatric patients compared to insulin glargine, particularly in younger children or obese adolescents.
The flat time-action profile of these basal analogues significantly reduces the risk of between-meal and nocturnal hypoglycemia compared to intermediate-acting NPH insulin.

Insulin degludec is the primary ultra-long-acting basal insulin analogue currently available.
It is engineered by coupling Des-B30 threonine insulin to a specific fatty acid side chain.
Following subcutaneous injection, insulin degludec molecules self-associate to form massive dihexameric chains.
These long chains of insulin remain in the subcutaneous tissue and dissociate into absorbable monomers very slowly and predictably over an extended period.

Insulin degludec possesses an onset of action of 0.5 to 1.5 hours, exhibits a completely flat, minimal peak, and has a highly prolonged duration of action exceeding 42 hours.
The systemic half-life of insulin degludec is prolonged to between 17 and 21 hours, which is roughly double the duration of action of insulin glargine.
It provides highly stable, reproducible basal coverage and has been shown to be safe and effective in children and adolescents with type 1 diabetes.

Mixing Insulins: While rapid-acting analogues (lispro, aspart, glulisine) can be safely mixed in the same syringe with intermediate-acting NPH insulin, they must never be mixed with long-acting analogues like glargine or detemir.
Mixing rapid-acting analogues with long-acting basal analogues significantly alters their pharmacodynamics, markedly blunting and delaying the peak absorption and action of the rapid-acting component.
CSII (Pump) Vulnerability: Because patients utilizing insulin pumps receive only continuous infusions of rapid-acting analogues without any long-acting basal depot, they are highly vulnerable to rapid metabolic decompensation.
If pump delivery is accidentally or purposefully interrupted (e.g., due to a kinked or occluded subcutaneous catheter), the short duration of the rapid-acting analogue means the patient will become absolutely insulin deficient and develop significant ketonemia and diabetic ketoacidosis (DKA) within 4 to 6 hours.